A5007652791- Colorectal Cancer Treatments and Studies
- Gastric Cancer Management and Outcomes
- Colorectal and Anal Carcinomas
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Pancreatic and Hepatic Oncology Research
- Genetic factors in colorectal cancer
- Cardiac tumors and thrombi
- Cancer, Lipids, and Metabolism
- Cancer Immunotherapy and Biomarkers
- Lipid metabolism and disorders
- Cancer, Hypoxia, and Metabolism
- Gastrointestinal Tumor Research and Treatment
- Cancer Treatment and Pharmacology
- Cell Adhesion Molecules Research
- Gastrointestinal disorders and treatments
- Esophageal Cancer Research and Treatment
- Immune Cell Function and Interaction
- Angiogenesis and VEGF in Cancer
- Cancer Genomics and Diagnostics
- Ferroptosis and cancer prognosis
- Lung Cancer Treatments and Mutations
- Immune cells in cancer
- Immunotherapy and Immune Responses
- Hepatocellular Carcinoma Treatment and Prognosis
- Inflammatory Biomarkers in Disease Prognosis
Université Clermont Auvergne
2023-2025
Inserm
2015-2024
L'Hôpital Nord Franche-Comté
2018-2024
Microbe, Intestine, Inflammation and Host Susceptibility
2023-2024
Centre Hospitalier Universitaire de Clermont-Ferrand
2023-2024
Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement
2024
Université de franche-comté
2015-2023
Hôpital Privé Jean Mermo
2023
Centre Hospitalier Universitaire de Besançon
2013-2022
Établissement Français du Sang
2021-2022
In patients with resectable gastric/gastroesophageal junction (GEJ) adenocarcinoma, surgery plus perioperative platinum-based chemotherapy is the standard of care. Perioperative remains debatable for gastric/GEJ adenocarcinoma deficient mismatch repair (dMMR)/microsatellite instability-high (MSI-H).NEONIPIGA (ClinicalTrials.gov identifier: NCT04006262) phase II study evaluated neoadjuvant nivolumab 240 mg once every two weeks ×6 and ipilimumab 1 mg/kg six ×2, followed by adjuvant 480 four...
244 Background: In pts with resectable gastric adenocarcinoma or OGA, radical surgery is the only curative option and perioperative chemotherapy seems worthless for those MSI/dMMR tumors. Methods: We conducted phase II study evaluating efficacy of neo-adjuvant nivolumab ipilimumab followed by adjuvant in MSI/dMMR, T2-T4 NxM0 Treatment consisted 240 mg every 2 weeks (6 infusions) 1 mg/kg 6 (2 infusions), 5 (±1 week) after last injection nivolumab. Pts Becker tumor regression grade (TRG) <...
Human colorectal cancers (CRCs) are readily colonized by colibactin-producing E. coli (CoPEC). CoPEC induces DNA double-strand breaks, mutations, genomic instability, and cellular senescence. Infected cells produce a senescence-associated secretory phenotype (SASP), which is involved in the increase tumorigenesis observed CRC mouse models infected with CoPEC. This study investigated whether CoPEC, SASP derived from CoPEC-infected cells, impacted chemotherapeutic resistance. intestinal...
PURPOSE GEMPAX was an open-label, randomized phase III clinical trial designed to assess the efficacy and tolerability of gemcitabine plus paclitaxel versus alone as second-line treatment for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) who previously received 5-fluorouracil, oxaliplatin, irinotecan. METHODS Patients histologically or cytologically confirmed mPDAC were randomly assigned (2:1) receive (paclitaxel 80 mg/m 2 + 1,000 ; IV; once at day (D) 1, D8, D15/arm A)...
PURPOSE The objective of this work was to establish prognostic models in stage III colon cancer (CC) on the basis transcriptomic signatures tumor microenvironment (TME) and cell cycle from PETACC-8 (training set) IDEA-France (validation trials. PATIENTS AND METHODS 3'RNA sequencing performed 1,733 patients trial 1,248 trial. Four were analyzed: T-cell macrophage M2 signatures, expression CXCL13, a score Oncotype DX CC Recurrence Score using same formula stromal score. Immune Proliferative...
Human papillomavirus (HPV) is found in 90% of squamous cell carcinomas the anal canal (SCCA). We investigated clinical validity HPV circulating tumor DNA (ctDNA) detection patients enrolled Epitopes-HPV02 trial that demonstrated efficacy docetaxel, cisplatin, and 5-FU as first-line chemotherapy advanced SCCA.According to protocol, serum samples were collected before on completion chemotherapy. HPV16 ctDNA was quantified by droplet digital PCR (ddPCR) correlated with prospectively registered...
Immune checkpoint blockade has proven its efficacy in hypermutated subtypes of metastatic colorectal cancers (mCRC). Immunogenic potential can also be observed with conventional chemotherapies, but this property never been explored thoroughly CRC patients. The therapeutic arsenal includes oxaliplatin, a well-characterized platinum drug already described as immunogenic. Here, we investigated the impact oxaliplatin-based treatment on mCRC immunopeptidome. We demonstrated that...
Several distinct innate lymphoid cell (ILC) populations have been recently identified and shown to play a critical role in the immediate immune defense. In context of tumors, there is evidence support dual for ILCs with pro- or antitumor effects, depending on ILC subset type cancer. This ambivalent has particularly well-described colorectal cancer models (CRC), but presence evolution peripheral blood metastatic CRC (mCRC) patients not yet explored. Here, we investigated distribution subsets...
Abstract Myeloid-derived suppressor cells (MDSC) promote immunosuppression and are a target in the field of immuno-oncology. Accumulation MDSCs is associated with poor prognosis resistance to immunotherapy for several cancers. Here, we describe an accumulation subset circulating monocytic (M-MDSC) overexpressing TIE2, receptor angiopoietin-2 (ANGPT2), patients non–small cell lung cancer (NSCLC). Greater numbers TIE2+ M-MDSCs were detected NSCLC compared healthy subjects, this correlated...
Hepatic epithelioid hemangioendothelioma is a rare liver mesenchymatous tumor with an epithelial aspect developed from endothelial cells lack of validated therapeutic options at metastatic stage. Metronomic chemotherapy has been described as anti-angiogenic therapy leading to the depletion circulating progenitors. We report results two patients treated for metronomic cyclophosphamide chemotherapy. Following initiation (50mg once day continuously), exhibited significant clinical improvement...
Pancreatic adenocarcinoma (PDAC) incidence is increasing worldwide. Several studies have shown that lymphopenia was correlated with a poor prognosis but the potential interest to measure in pre and post-operative setting as well its added value among conventional prognostic factors never investigated. Data from two independent cohorts whom patients underwent resection for pancreatic carcinoma were retrospectively recorded. We examined association between perioperative findings, lymphocyte...
Despite successful introduction of NK-based cellular therapy in the treatment myeloid leukemia, potential use NK alloreactivity solid malignancies is still elusive. We performed a phase I clinical trial to assess safety and efficacy situ delivery allogeneic cells combined with cetuximab liver metastasis gastrointestinal origin. The conditioning chemotherapy was administrated before injection via hepatic artery. Three escalating doses were tested (3.106, 8.106 12.106 cells/kg) following by...
Background The positive role of CD8+ tumor-infiltrating lymphocytes (TIL) in patients with colorectal cancer (CRC) has been well described but the prognostic value CD4 T cell subsets remained to be investigated. In this study, we expanded TIL from surgically resected liver metastases CRC and characterized phenotype expanded-CD4 cells. Methods Liver were 23 CRC. Tumors enzymatically digested cultured high dose interleukin-2 for up 5 weeks. reactivity cultured-T cells measured by flow...
Aims: The addition of docetaxel to cisplatin and 5-fluorouracil (DCF) has shown promising efficacy in advanced squamous cell carcinoma the anus (SCCA). Preliminary results Epitopes-HPV01 study showed a high rate long-lasting complete response DCF. prospective, multicenter, Epitopes-HPV02 trial then confirmed modified DCF (mDCF) regimen terms long-term survival metastatic or non-resectable locally recurrent SCCA. Here, we present updated studies. Patients & methods: is prospective...
Abstract Background Modified docetaxel, cisplatin, and 5-fluorouracil (mDCF) regimen has become a new standard for the treatment of metastatic or unresectable locally advanced recurrent squamous cell carcinoma anus (SCCA) after demonstrating improved efficacy (12-month PFS 47%) in Epitopes-HPV02 trial. Antibodies targeting checkpoint inhibitor (CKI) programmed death protein-1 (PD1) have demonstrated as monotherapies second-line SCCA. The aim this study is to evaluate combination atezolizumab...
Bevacizumab shows inter-individual pharmacokinetic variability, with an exposure-response relationship in metastatic colorectal cancer (mCRC) patients. This study explores whether a double dose of bevacizumab, compared to standard dose, increases efficacy mCRC patients treated bevacizumab-based chemotherapy as first-line therapy and who have low initial trough concentration bevacizumab. PHARBEVACOL is multicenter, randomized, double-blind, two-parallel group trial. All will receive bi-weekly...
Regorafenib is an orally administered multikinase inhibitor that has been approved for patients with chemotherapy-refractory metastatic colorectal cancer (mCRC). Even though regorafenib significantly improved survival in two international phase 3 trials (CORRECT and CONCUR), a high rate of treatment-related toxic effects dose modifications were observed modest benefit. The aim this study was to provide information concerning the efficacy, safety, cost mCRC clinical practice.We...